Back

In vitro activity of tigecycline and linezolid against nosocomial MRSA strains

Abstract number: 1733_1531

Kaya O., Akcam F., Temel E.

Objective: Methicillin-resistant Staphylococcus aureus (MRSA) has become one of the most widespread causes of nosocomial infections worldwide. Moreover, it has been recovered from community-acquired infections. Therapeutic options for these infections are limited.

Research for new antimicrobial agent is perpetuated for treatment of this infections. Tigecycline is the first drug in the glycylcycline class of antibiotics. Linezolid is a synthetic antimicrobial agent of the an oxazolidinone class. The aim of this study is to evaluate MIC50 and MIC90 values of tigecycline and linezolid against MRSA strains.

Methods: A total of 60 MRSA strains isolated from various clinical specimens and at different times were included in the study. All the isolates were stored at -80°C when they had been isolated. These isolates were identified as S. aureus by phenotypic characteristics, Gram staining, catalase and coagulase tests. Resistance to methicillin was confirmed using the Mueller-Hinton agar diffusion procedure with 1 mg oxacillin disks, as recommended by the Clinical and Laboratory Standards Institute (CLSI). Minimal inhibitory concentrations (MIC) were determined by the E-test method, according to the CLSI criteria.

Results: All isolates were sensitive to linezolid and tygecycline. The MIC levels of both antibiotics are listed in the table.

AntibioticRange (mg/mL)MIC50 (pg/mL)MIC90 (mg/mL)
Tigecycline0.032–1.00.1250.38
Linezolid0.094–40.501

Conclusion: In conclusion, given the limited therapeutic options for serious MRSA infections, tigecycline and linezolid may offer additional options as they demonstrated good activity against clinical strains of MRSA infections.

Session Details

Date: 31/03/2007
Time: 00:00-00:00
Session name: European Society of Clinical Microbiology and Infectious Diseases
Subject:
Location: ICC, Munich, Germany
Presentation type:
Back to top